Last updated: August 29, 2026
Capozide 50/25 is a fixed-dose antihypertensive containing captopril 50 mg and hydrochlorothiazide 25 mg. Its commercial trajectory is mature to declining: the product has no meaningful remaining exclusivity, competes with low-cost generic captopril/hydrochlorothiazide and separate-component therapy, and has limited strategic value for branded pharmaceutical companies. Public filings do not report standalone Capozide revenue, indicating that any historical sales were immaterial to Bristol-Myers Squibb's consolidated financial results.
What is Capozide 50/25 and how is it used?
Capozide 50/25 combines an angiotensin-converting enzyme inhibitor, captopril, with the thiazide diuretic hydrochlorothiazide. Each tablet contains:
| Product |
Captopril |
Hydrochlorothiazide |
| Capozide 50/25 |
50 mg |
25 mg |
The product was approved for hypertension in patients who require combination treatment or who do not achieve adequate blood-pressure control with monotherapy. The FDA label states that captopril reduces angiotensin II formation, while hydrochlorothiazide promotes sodium and fluid excretion.[1]
Captopril has a short duration of action compared with several newer ACE inhibitors. The label historically supported divided dosing, which creates a commercial disadvantage against once-daily combinations such as lisinopril/hydrochlorothiazide and losartan/hydrochlorothiazide.[1]
What therapeutic category does Capozide belong to?
Capozide is a small-molecule, fixed-dose ACE inhibitor/thiazide combination. It competes in the following categories:
- ACE inhibitor plus thiazide combinations
- Angiotensin receptor blocker plus thiazide combinations
- Calcium-channel blocker combinations
- Separate generic captopril and hydrochlorothiazide prescriptions
- Single-agent antihypertensive therapy
The product is not a biologic and has no biosimilar exposure. Its principal competitive threat is generic substitution.
What is the FDA regulatory status of Capozide 50/25?
Capozide was approved through the FDA's new drug application pathway as a branded prescription drug. Current product availability is limited compared with the period when Bristol-Myers Squibb marketed the brand. FDA labeling and drug databases distinguish between a product being discontinued for commercial reasons and being withdrawn for safety or efficacy reasons.[1][2]
The product's commercial position is consistent with an older discontinued or commercially inactive brand:
| Regulatory issue |
Capozide 50/25 assessment |
| Active branded growth product |
No |
| Biologic |
No |
| Biosimilar pathway |
Not applicable |
| Current commercial franchise |
Minimal |
| Generic substitution risk |
Very high |
| FDA safety withdrawal identified in standard labeling |
No |
| Fixed-dose combination |
Yes |
The precise current availability of any particular manufacturer's 50/25-strength generic depends on distributor inventories, national drug databases, and manufacturer marketing decisions. Generic captopril/hydrochlorothiazide products may appear under abbreviated new drug applications rather than under the Capozide brand.
What patents protect Capozide 50/25?
Capozide 50/25 has no commercially meaningful patent barrier. The relevant foundational captopril patent, U.S. Patent No. 4,046,889, issued in 1977 and expired decades ago.[3] Hydrochlorothiazide was also an established generic drug long before Capozide's commercial life.
The estate can be analyzed in four layers:
| Protection layer |
Current commercial impact |
| Captopril compound patent |
Expired |
| Hydrochlorothiazide compound protection |
Expired |
| Fixed-dose combination patents |
Expired or commercially irrelevant |
| Method-of-use patents |
No meaningful current barrier identified |
| Manufacturing patents |
No barrier to routine generic production identified |
What formulations are protected by Capozide patents?
The commercial formulation is a conventional immediate-release tablet containing captopril and hydrochlorothiazide. It does not depend on a complex delivery system, extended-release technology, device, depot formulation, or specialized manufacturing platform.
Any historical formulation or combination patents would have expired before the current generic market. There is no apparent formulation feature that can support modern lifecycle management comparable with controlled-release tablets, transdermal systems, injectable products, or branded combination devices.
What is the Orange Book status of Capozide?
The FDA Orange Book is the relevant source for listed patents, exclusivity, therapeutic-equivalence evaluations, and discontinued-product status.[2] Capozide's practical Orange Book position is that of an aged small-molecule product without enforceable branded exclusivity.
No current patent listing appears to create a meaningful barrier to an ANDA applicant for generic captopril/hydrochlorothiazide 50/25. Product-specific listing status should be distinguished from the broader issue of whether any manufacturer still actively markets a particular generic NDC.
When did Capozide lose exclusivity?
Capozide lost effective exclusivity in the 1990s or earlier as the underlying captopril and combination protections expired. The exact commercial loss of exclusivity occurred through the normal sequence for an older small-molecule drug:
- Expiration of the foundational captopril patent.
- Expiration of any relevant combination or formulation protection.
- FDA approval of generic equivalents.
- Price erosion as multiple manufacturers entered.
- Brand withdrawal or reduction in commercial support.
There is no current new chemical entity exclusivity, orphan-drug exclusivity, pediatric exclusivity, or six-month Paragraph IV exclusivity of commercial significance for the branded product.
Are there Paragraph IV challenges to Capozide 50/25?
Paragraph IV litigation is not a current commercial issue for Capozide. Paragraph IV certifications challenge listed patents as invalid, unenforceable, or not infringed. They matter when a branded product has active Orange Book patents that delay or threaten generic entry.
For Capozide, the relevant patents expired long ago. The likely entry route for a modern generic is a standard ANDA relying on reference-product safety and efficacy, not a strategically important patent challenge against an active branded estate.[2][4]
No active, commercially significant Capozide Paragraph IV dispute or settlement agreement is identified in the standard FDA and public litigation record.
What patent litigation affects Capozide?
There is no known current patent litigation that materially affects Capozide 50/25 market access. The absence of active litigation reflects the product's age, the expiration of foundational patents, and the low value of defending a legacy antihypertensive brand.
Potential disputes involving generic manufacturing, supply contracts, trademarks, or distribution would be separate from patent litigation over the active pharmaceutical ingredients or the fixed-dose formulation.
How strong is the Capozide patent estate?
The estate is commercially weak.
| Patent-strength factor |
Assessment |
| Remaining term |
None of strategic value |
| Active composition-of-matter protection |
None |
| Formulation differentiation |
Low |
| Manufacturing complexity |
Low to moderate |
| Method-of-use protection |
No meaningful current protection |
| Litigation leverage |
Minimal |
| Generic entry deterrence |
Minimal |
| Licensing value |
Minimal |
The only potentially defensible areas would involve manufacturing know-how, quality-control procedures, supplier qualification, or proprietary distribution arrangements. Those are operational assets, not barriers comparable with an unexpired pharmaceutical patent.
How does Capozide compare with competing antihypertensive combinations?
Capozide is disadvantaged by the age and dosing characteristics of captopril. The combination remains pharmacologically understandable, but treatment guidelines and prescribing practice have shifted toward longer-acting agents and other first-line combinations.[5]
| Combination |
Commercial position versus Capozide |
| Lisinopril/hydrochlorothiazide |
Stronger once-daily positioning and broad generic availability |
| Enalapril/hydrochlorothiazide |
Established generic competitor |
| Losartan/hydrochlorothiazide |
Major ARB/thiazide alternative; useful where ACE-inhibitor cough is a concern |
| Valsartan/hydrochlorothiazide |
Generic ARB/thiazide alternative |
| Captopril plus separate hydrochlorothiazide |
Direct therapeutic and economic substitute |
| Amlodipine-based combinations |
Strong alternative in hypertension treatment algorithms |
Captopril retains clinical utility in selected patients, but the fixed-dose Capozide presentation has limited differentiation. Physicians can prescribe separate generic components and adjust one ingredient independently, which can be clinically preferable when titration is required.
What is the financial trajectory of Capozide?
Capozide's financial trajectory is best characterized as:
branded launch and adoption -> generic erosion -> low-price mature product -> commercial discontinuation or residual niche sales.
Bristol-Myers Squibb does not report Capozide as a separately material revenue line in its public financial statements. The absence of product-level revenue disclosure prevents a defensible reconstruction of annual Capozide sales, gross margin, or contribution profit from public filings.[6]
Revenue exposure
Capozide has negligible current revenue exposure for the original innovator. Its commercial value is constrained by:
- No patent-protected price premium
- Multiple therapeutic substitutes
- Generic availability
- Low prescription reimbursement rates
- Limited brand promotion
- No differentiated delivery technology
- No biologic manufacturing moat
For a generic manufacturer, the product may generate modest unit volume but generally has low revenue per tablet and limited margin protection. Profitability depends on manufacturing scale, procurement costs, shortage conditions, and whether the manufacturer has a stable customer base.
Generic pricing dynamics
The 50/25 tablet is a mature commodity product. Price behavior is typically driven by:
- Number of approved suppliers
- Active marketed NDCs
- Wholesaler purchasing patterns
- Hospital and retail contracting
- API cost and availability
- Manufacturing-site disruptions
- FDA compliance events
- Temporary shortages
The product can experience short-term price increases if supply contracts or manufacturing interruptions reduce competition. Such increases would reflect supply tightness rather than durable market power.
Which companies are challenging or competing with Capozide?
The principal competitors are not branded challengers but manufacturers of generic captopril/hydrochlorothiazide and producers of alternative fixed-dose antihypertensives. Generic competition can arise from manufacturers such as Teva, Mylan or Viatris, Sandoz, Zydus, Lupin, Dr. Reddy's, and other ANDA holders, depending on current marketing status and product availability.
The relevant competitive set includes:
- Generic captopril/hydrochlorothiazide 50/25.
- Generic captopril tablets combined with separate hydrochlorothiazide.
- Lisinopril/hydrochlorothiazide.
- Losartan/hydrochlorothiazide.
- Enalapril/hydrochlorothiazide.
- Valsartan/hydrochlorothiazide.
The competitive market is fragmented by payer formularies and pharmacy sourcing. No single manufacturer is likely to maintain a durable branded position without supply reliability, low manufacturing cost, or a temporary shortage advantage.
What generic entry risks exist for Capozide?
Generic entry risk is effectively realized rather than prospective. The primary risks are market-share dilution and price compression, not future patent invalidation.
Generic launch scenarios
| Scenario |
Likely outcome |
| Multiple generic suppliers |
Lowest prices and limited manufacturer margins |
| One or two active suppliers |
Better pricing but greater shortage exposure |
| Brand withdrawal with continued generic supply |
Generic substitution becomes standard |
| Manufacturing disruption |
Temporary price and availability volatility |
| Reimbursement exclusion |
Rapid prescription migration to alternatives |
| Shortage of 50/25 strength |
Substitution with separate components or other ACE/thiazide combinations |
The most probable long-term scenario is continued low-volume generic availability with intermittent supply variability. A branded relaunch would require a clear supply, convenience, or reimbursement advantage that the current product profile does not provide.
What geographic coverage does Capozide have?
Capozide's meaningful commercial relevance is primarily historical and U.S.-focused. U.S. market access depends on FDA-approved labeling, Orange Book status, ANDA competition, and pharmacy distribution.
Outside the United States, captopril/hydrochlorothiazide combinations may remain available under local brands or generic names. International commercial opportunity is constrained by:
- Mature generic competition
- National tender systems
- Low reimbursement prices
- Local registration requirements
- Low switching costs
- Availability of separate captopril and hydrochlorothiazide
Geographic expansion would not create strong IP value because the core ingredients and conventional tablet formulation are long established.
What licensing deals affect Capozide?
No strategically material current licensing deal is associated with Capozide 50/25. Historical commercialization was tied to Bristol-Myers Squibb's branded portfolio, but the product does not appear to have a current licensing profile comparable with an actively managed specialty or biologic product.
A transaction involving Capozide today would more likely concern a generic portfolio, product rights, or a discontinued-product asset package. Its value would be based on manufacturing rights, regulatory files, supply capacity, and distribution relationships rather than patent exclusivity.
Key Takeaways
- Capozide 50/25 contains captopril 50 mg and hydrochlorothiazide 25 mg.
- The product is an old, conventional immediate-release antihypertensive combination.
- Foundational patent protection expired decades ago.
- No active patent estate creates a meaningful barrier to generic entry.
- Paragraph IV litigation and settlement risk are not material current issues.
- The product has no biosimilar risk because it is a small molecule.
- Its main competitors are generic captopril/hydrochlorothiazide, separate-component therapy, and newer once-daily ACE/ARB combinations.
- Bristol-Myers Squibb does not publicly disclose standalone Capozide revenue.
- The financial trajectory is mature to declining, with residual value concentrated in generic supply rather than branded pricing.
- Manufacturing reliability and distribution access matter more than intellectual property.
FAQs
Is Capozide 50/25 still sold under the brand name?
The brand has limited commercial relevance, and prescriptions are more likely to be filled through generic captopril/hydrochlorothiazide or separate-component products.
Is Capozide 50/25 therapeutically equivalent to generic captopril/hydrochlorothiazide?
An FDA-approved generic rated therapeutically equivalent to the reference product can generally be substituted under applicable state pharmacy law. Product-specific availability and substitution depend on the FDA Orange Book and the dispensing pharmacy.[2]
Can a company obtain new patents on Capozide 50/25?
A new patent could theoretically cover a genuinely novel formulation, manufacturing process, or use. The conventional 50/25 tablet itself is unlikely to support commercially meaningful new patent protection because the active ingredients and basic combination are long established.
Does Capozide have exclusivity similar to newer hypertension drugs?
No. Capozide does not have current new chemical entity, orphan-drug, or clinically meaningful market exclusivity.
What is the most important commercial risk for a Capozide generic manufacturer?
The main risks are low net pricing, limited prescription growth, supplier consolidation, API or manufacturing disruption, and substitution by once-daily ACE inhibitor or ARB combinations.
References
- U.S. Food and Drug Administration. (n.d.). Capozide: Captopril and hydrochlorothiazide tablets prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (1977). U.S. Patent No. 4,046,889: Proline derivatives.
- U.S. Food and Drug Administration. (n.d.). Generic drugs: ANDA approvals and patent certifications.
- Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
- Bristol-Myers Squibb Company. (n.d.). Annual reports and Securities and Exchange Commission filings.
